Home Featured Page 10

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with...

A Rundown of Colorado’s Natural Medicine Program

SXSW Psychedelics Conference 2025

Psychedelic Culture by Chacruna Institute

Bicycle Day 2025 @ Meow Wolf Denver

Forging a Path to Access: Congressmen Correa and Bergman on the...

Neil Markey – Beckley Retreats

Pα+ Psychedelic Bulletin #189: Psychedelic Philanthropists Weigh In on New Administration;...

Psychedelic Policy Push Continues: Over 60 Bills Introduced Across 22 States

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files...

1...91011...292 Page 10 of 292

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with...

A Rundown of Colorado’s Natural Medicine Program

SXSW Psychedelics Conference 2025

Psychedelic Culture by Chacruna Institute

Bicycle Day 2025 @ Meow Wolf Denver

Forging a Path to Access: Congressmen Correa and Bergman on the...

Neil Markey – Beckley Retreats

Pα+ Psychedelic Bulletin #189: Psychedelic Philanthropists Weigh In on New Administration;...

Psychedelic Policy Push Continues: Over 60 Bills Introduced Across 22 States

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files...

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY